Molecular Dissection of Interactions between Components of the Alternative Pathway of Complement and Decay Accelerating Factor (CD55)*
暂无分享,去创建一个
B. Paul Morgan | Susan M. Lea | Claire L. Harris | R. Smith | S. Lea | B. Morgan | B. Morgan | C. Harris | Rachel J. M. Abbott | Richard A. Smith | R. Abbott | Richard A. Smith
[1] G. Smith,et al. Biological activity, membrane‐targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli , 2004, Protein science : a publication of the Protein Society.
[2] O. Spiller,et al. Mapping CD55 Function , 2003, The Journal of Biological Chemistry.
[3] Martin Stacey,et al. Molecular Analysis of the Epidermal Growth Factor-like Short Consensus Repeat Domain-mediated Protein-Protein Interactions , 2001, The Journal of Biological Chemistry.
[4] M. Shoham,et al. Molecular modeling and mechanism of action of human decay-accelerating factor. , 1996, Protein engineering.
[5] A. Wardlaw,et al. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. , 1954, Science.
[6] A. Day,et al. Structure-function relationships of the complement components. , 1989, Immunology today.
[7] B. Nilsson,et al. Complement C3b interactions studied with surface plasmon resonance technique. , 2001, International immunopharmacology.
[8] G. Ball,et al. Solution structure of a functionally active fragment of decay-accelerating factor , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[9] T. Fujita,et al. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor. , 1992, Journal of immunology.
[10] D. Lublin,et al. Efficient generation of monoclonal antibodies for specific protein domains using recombinant immunoglobulin fusion proteins: pitfalls and solutions. , 2002, Journal of immunological methods.
[11] John D Lambris,et al. The multifunctional role of C3: structural analysis of its interactions with physiological ligands. , 1986, Molecular immunology.
[12] D. Stuart,et al. Determination of the Affinity and Kinetic Constants for the Interaction between the Human Virus Echovirus 11 and Its Cellular Receptor, CD55* , 1998, The Journal of Biological Chemistry.
[13] O. Götze,et al. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway , 1976, The Journal of experimental medicine.
[14] R. Levine,et al. Interaction between the third complement protein and cell surface macromolecules. , 1977, Proceedings of the National Academy of Sciences of the United States of America.
[15] H. Müller-Eberhard,et al. The cobra venom factor-dependent C3 convertase of human complement. A kinetic and thermodynamic analysis of a protease acting on its natural high molecular weight substrate. , 1982, The Journal of biological chemistry.
[16] S. Perkins,et al. Metal-dependent conformational changes in a recombinant vWF-A domain from human factor B: a solution study by circular dichroism, fourier transform infrared and (1)H NMR spectroscopy. , 2000, Journal of Molecular Biology.
[17] P. Nicol,et al. The alternate pathway of complement activation. The role of C3 and its inactivator (KAF). , 1973, Immunology.
[18] W. Dames,et al. Complement activation by the properdin system: formation of a stoichiometric. C3 cleaving complex of properdin factor B with C36. , 1977, Immunochemistry.
[19] P. Lachmann,et al. The physiological breakdown of the third component of human complement. , 1980, Molecular immunology.
[20] R. Schreiber,et al. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3 , 1981, The Journal of experimental medicine.
[21] N. Cooper. FORMATION AND FUNCTION OF A COMPLEX OF THE C3 PROACTIVATOR WITH A PROTEIN FROM COBRA VENOM , 1973, The Journal of experimental medicine.
[22] N. Cooper,et al. The structure and function of the third component of human complement--I. The nature and extent of conformational changes accompanying C3 activation. , 1981, Molecular immunology.
[23] Robert B Sim,et al. Production and functional activity of a recombinant von Willebrand factor-A domain from human complement factor B. , 1999, The Biochemical journal.
[24] D. Hourcade,et al. Decay acceleration of the complement alternative pathway C3 convertase. , 1999, Immunopharmacology.
[25] S. Lea. Interactions of CD55 with non-complement ligands. , 2001, Biochemical Society transactions.
[26] D. Hourcade,et al. Decay-accelerating Factor (DAF), Complement Receptor 1 (CR1), and Factor H Dissociate the Complement AP C3 Convertase (C3bBb) via Sites on the Type A Domain of Bb* , 2002, The Journal of Biological Chemistry.
[27] J. Lambris,et al. Dissection of CR1, factor H, membrane cofactor protein, and factor B binding and functional sites in the third complement component. , 1996, Journal of immunology.
[28] M. Pangburn,et al. Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties. , 1981, Biochemistry.
[29] Z. Fishelson,et al. Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b,Bb. , 1984, Journal of immunology.
[30] C. Mold,et al. Structure/function studies of human decay‐accelerating factor , 2000, Immunology.
[31] S. Perkins,et al. Conformational changes during the assembly of factor B from its domains by (1)H NMR spectroscopy and molecular modelling: their relevance to the regulation of factor B activity. , 2000, Journal of molecular biology.
[32] D. Hourcade,et al. Characterization of the Active Sites in Decay-Accelerating Factor1 , 2001, The Journal of Immunology.
[33] Z. Fishelson,et al. C3 convertase of the alternative complement pathway. Demonstration of an active, stable C3b, Bb (Ni) complex. , 1983, The Journal of biological chemistry.
[34] T. Fujita,et al. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb , 1987, The Journal of experimental medicine.
[35] J. Atkinson,et al. Competition for binding sites on C3b by CR1, CR2, MCP, factor B and factor H. , 1990, Complement and inflammation.
[36] J. Volanakis,et al. Surface loops adjacent to the cation-binding site of the complement factor B von Willebrand factor type A module determine C3b binding specificity. , 1997, Biochemistry.
[37] B. Morgan,et al. Complement Regulatory Proteins , 1999 .
[38] Pietro Roversi,et al. An atomic resolution model for assembly, architecture, and function of the Dr adhesins. , 2004, Molecular cell.
[39] M. Pangburn,et al. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases. , 1986, Journal of immunology.
[40] E. Pryzdial,et al. Alternative complement pathway activation fragment Ba binds to C3b. Evidence that formation of the factor B-C3b complex involves two discrete points of contact. , 1987, The Journal of biological chemistry.
[41] J. Atkinson,et al. Human C3b- and C4b-regulatory proteins: a new multi-gene family. , 1985, Immunology today.
[42] P Lukacik,et al. Complement regulation at the molecular level: the structure of decay-accelerating factor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[43] S. Narayana,et al. Complement factor D, a novel serine protease , 1996, Protein science : a publication of the Protein Society.